KahnSRShrierIJulianJA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Internal Med2008; 149: 698–707.
2.
EndenTHaigYKløwN-E, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): A randomised controlled trial. Lancet2012; 379: 31–38.
3.
VedanthamSGoldhaberSZJulianJA, et al.; for the ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med2017; 377: 2240–2252.
4.
PrandoniPLensingAWCogoA, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med1996; 125: 1–7.
5.
ComerotaAJGrewalNMartinezJT, et al. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg2012; 55: 768–773.
6.
StevensSMWollerSCKreuzigerLB, et al. Antithrombotic therapy for VTE disease: Compendium and review of CHEST guidelines 2012–2021. Chest2024; 166: 388–404.
7.
KakkosSKGohelMBaekgaardN, et al. Editor’s Choice–European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg2021; 61: 9–82.
8.
LichtenbergMKStahlhoffSMłyńczakK, et al. Endovascular mechanical thrombectomy versus thrombolysis in patients with iliofemoral deep vein thrombosis–A systematic review and meta-analysis. Vasa2021; 50: 59–67.
9.
ShaikhAZybulewskiAPaulisinJ, et al. Six-month outcomes of mechanical thrombectomy for treating deep vein thrombosis: Analysis from the 500-patient CLOUT registry. Cardiovasc Intervent Radiol2023; 46: 1571–1580.
10.
BabigumiraJBBlackSALubingaSJPounceyAL.Cost effectiveness of early endovenous thrombus removal for acute iliofemoral deep vein thrombosis in the United Kingdom. Eur J Vasc Endovasc Surg2024; 67: 490–498.
11.
GoldhaberSZMagnusonEAChinnakondepalliKM, et al. Catheter-directed thrombolysis for deep vein thrombosis: 2021 update. Vasc Med2021; 26: 662–669.
12.
NottenPTen Cate-HoekAJArnoldussenC, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): A single-blind, multicentre, randomised trial. Lancet Haematol2020; 7: e40–e49.
13.
MilinisKThaparAShalhoubJDaviesAH.Antithrombotic therapy following venous stenting: International Delphi Consensus. Eur J Vasc Endovasc Surg2018; 55: 537–544.
14.
DesaiKRSabriSSEliasS, et al. Consensus Statement on the management of nonthrombotic iliac vein lesions from the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society. Circ Cardiovasc Interv2024; 17: e014160.
15.
SchulmanSKonstantinidesSHuYTangLV.Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing: Observations on NICE Guideline [NG158]. Thromb Haemost2020; 120: 1143–1146.
16.
VedanthamSDesaiKRWeinbergI, et al. Society of Interventional Radiology Position Statement on the Endovascular Management of Acute Iliofemoral Deep Vein Thrombosis. J Vasc Intervent Radiol2023; 34: 284–299.e7.
17.
WuCAlotaibiGSAlsalehKSean McMurtryM.Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: A systematic review. Thromb Res2014; 134: 627–632.
18.
HaysKJollyMSilverM, et al. Outcomes of endovascular venous stenting in patients on direct oral anticoagulants and antiplatelet therapy at a tertiary referral center. J Vasc Surg Venous Lymphat Disord2021; 9: 753–759.e1.
19.
WeitzJILensingAWAPrinsMH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med2017; 376: 1211–1222.
20.
AgnelliGBullerHRCohenA, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med2013; 368: 699–708.
21.
SchulmanSKearonCKakkarAK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med2013; 368: 709–718.
22.
XiaoNGenetMKhajaMDesaiKR.Antithrombotic therapy after deep venous intervention. Semin Intervent Radiol2022; 39: 357–363.
23.
TranMALakhanpalPLakhanpalS, et al. Type of anti-thrombotic therapy for venous stenting in patients with non-thrombotic iliac vein lesions does not influence the development of in-stent restenosis. Phlebology2020; 35: 805–813.
24.
LinCMartinKAWangM, et al. Long-term antithrombotic therapy after venous stent placement. Phlebology2020; 35: 402–408.
25.
Del GiudiceCMaheGThonyF, et al. Venous recanalisation in the setting of post-thrombotic syndrome: An expert consensus from the French Society of Vascular Medicine (SFMV) and the French Society of Cardiovascular Imaging and Interventional Radiology (SFICV). J Med Vasc2024; 49: 141–161.
26.
RajuSNeglénP.Percutaneous recanalization of total occlusions of the iliac vein. J Vasc Surg2009; 50: 360–368.
27.
RajuSNeglenP.High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: A permissive role in pathogenicity. J Vasc Surg2006; 44: 136–144.
28.
BarcoSJalaieHSebastianT, et al. Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: The multicenter, multinational, randomized, Open-Label ARIVA trial. Circulation2025; 151: 835–846.
